Product Code: GDHC525DFR
Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.
Tenapanor is being developed for the treatment of IBS-C. It was initially developed by Ardelyx, but in October 2012, the company entered into a partnership with AstraZeneca, which gained the exclusive worldwide licensing rights to tenapanor (Ardelyx, press release, October 8, 2012).
Scope
- Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Tenapanor including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Tenapanor for the top 7 countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, and Japan.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for IBS.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Tenapanor performance.
- Obtain sales forecast for Tenapanor from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, the UK, and Japan).
Table of Contents
1. Table of Contents
- 1.1. List of Tables
- 1.2. List of Figures
2. Introduction
- 2.1. Catalyst
- 2.2. Related Reports
3. Disease Overview
- 3.1. Etiology and Pathophysiology
- 3.1.1. Etiology
- 3.1.2. Pathophysiology
- 3.2. Classification
- 3.3. Symptoms
- 3.4. Prognosis
- 3.5. Quality of Life
4. Disease Management
- 4.1. Diagnosis and Treatment Overview
- 4.1.1. Diagnosis
- 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
- 4.1.3. Clinical Practice
5. Competitive Assessment
6. Unmet Need and Opportunity
- 6.1. Overview
- 6.2. More Effective Pharmacotherapies
- 6.2.1. Unmet Need
- 6.2.2. Gap Analysis
- 6.2.3. Opportunity
- 6.3. Therapies for the IBS-D Subtype
- 6.3.1. Unmet Need
- 6.3.2. Gap Analysis
- 6.3.3. Opportunity
- 6.4. Therapies for the IBS-M Subtype
- 6.4.1. Unmet Need
- 6.4.2. Gap Analysis
- 6.4.3. Opportunity
- 6.5. Therapies to Address Abdominal Pain and Bloating Symptoms
- 6.5.1. Unmet Need
- 6.5.2. Gap Analysis
- 6.5.3. Opportunity
- 6.6. Improved Diagnosis Rate for IBS
- 6.6.1. Unmet Need
- 6.6.2. Gap Analysis
- 6.6.3. Opportunity
7. Pipeline Assessment
- 7.1. Overview
- 7.2. Promising Drugs in Clinical Development
8. Tenapanor (AZD1722, RDX5791)
- 8.1. Overview
- 8.2. Efficacy
- 8.3. Safety
- 8.4. Dosing and Formulation
- 8.5. Potential Clinical and Commercial Positioning
8.6. SWOT Analysis
9. Appendix
- 9.1. Bibliography
- 9.2. Abbreviations
- 9.3. Methodology
- 9.4. Forecasting Methodology
- 9.4.1. Diagnosed IBS Patients
- 9.4.2. General Pricing Assumptions
- 9.4.3. Generic Erosion
- 9.4.4. Pricing of Pipeline Agents
- 9.5. Primary Research - KOLs Interviewed for This Report
- 9.6. Primary Research - Prescriber Survey
- 9.7. About the Authors
- 9.7.1. Analyst
- 9.7.2. Therapy Area Director
- 9.7.3. Global Head of Healthcare
- 9.8. About GlobalData
- 9.9. Disclaimer
List of Tables
- Table 1: Common Symptoms of IBS
- Table 2: Summary of the Various Diagnostic Criteria Used for the Diagnosis of IBS
- Table 3: Treatment Guidelines for IBS
- Table 4: Leading Prescribed Drugs for IBS by Predominant Symptoms in the 7MM, 2014†
- Table 5: Leading Branded Treatments for IBS, 2014
- Table 6: Unmet Needs and Opportunities in IBS
- Table 7: Drugs in Late-Stage Clinical Development for IBS, 2014
- Table 8: Product Profile - Tenapanor
- Table 9: Tenapanor SWOT Analysis, 2014
- Table 10: Global IBS Sales Forecasts ($m) for Tenapanor, 2013-2023
- Table 11: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country
List of Figures
- Figure 1: Summary of Pharmacotherapies Used to Treat IBS
- Figure 2: IBS - Phase IIb-III Pipeline, October 2014
- Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in IBS, 2013-2023
- Figure 4: Clinical and Commercial Positioning of Tenapanor
